Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 26;9(16):4190-4194.
doi: 10.1182/bloodadvances.2025016748.

Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy

Jessica S Little  1   2 , Angelica Medina Pena  2 , E Bridget Kim  3 , Andrew J Yee  3 , Omar Nadeem  1 , Shonali Midha  1 , Adam S Sperling  1   4 , Nikhil C Munshi  1 , Noopur Raje  3 , Matthew J Frigault  3 , Diana D Cirstea  3 , Sarah P Hammond  1   3   5
Affiliations

Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy

Jessica S Little et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: J.S.L. reports research funding from Merck and consulting for Basilea. A.J.Y. reports consulting for AbbVie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Celgene, GSK, Johnson & Johnson, Karyopharm, Oncopeptides, Pfizer, Prothena, Regeneron, Sanofi, Sebia, and Takeda; and receives research funding from Amgen, Bristol Myers Squibb, GSK, Johnson & Johnson, and Sanofi. O.N. reports consulting or advisory role with Bristol Myers Squibb, Janssen, Takeda, Sanofi, Pfizer, and GPCR Therapeutics Inc.; research funding from Bristol Myers Squibb, Janssen, and Takeda; and honoraria from Pfizer. S.M. reports consulting for Janssen and Pfizer; honoraria for Pfizer; and stock ownership with AbbVie. A.S.S. reports consulting for Novartis. N.C.M. reports consulting for Bristol Myers Squibb, Janssen, Oncopep, Amgen, Karyopharm, Legened, AbbVie, Takeda, and GSK; and serves on the board of directors of, and has stock options in, Oncopep. N.R. reports consulting for AbbVie, Amgen, Bristol Myers Squibb, Janssen, Pfizer, Immuneel, GSK, K36 Therapeutics, Sanofi, and AstraZeneca; and research funding from Pfizer. M.J.F. reports consulting for Novartis, Kite/Gilead, Bristol Myers Squibb, JnJ/Legend, and SOBI; and receives research support from SOBI. S.P.H. reports consulting or advisory board roles for Pfizer, Roche, Melinta, Seres therapeutics, Takeda, and Treeline biosciences; and research funding from GSK, Scynexis, F2G, Cidara, and Mundipharma. The remaining authors declare no competing financial interests.

References

    1. Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–716. - PubMed
    1. Sidana S, Patel KK, Peres LC, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. Blood. 2025;145(1):85–97. - PMC - PubMed
    1. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. The Lancet. 2021;398(10 297):314–324. - PubMed
    1. Cordas Dos Santos DM, Tix T, Shouval R, et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med. 2024;30(9):2667–2678. - PMC - PubMed
    1. Rejeski K, Wang Y, Hansen DK, et al. Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Blood Adv. 2024;8(8):1857–1868. - PMC - PubMed